HLA-B*59 Product Insert Page 1 of 12

101.554-06u - without *Taq* polymerase

General "Instructions for Use" IFU-02 Rev. No. 02 can be downloaded from

Lot No.: 95K Lot-specific information www.olerup-ssp.com

Olerup SSP® HLA-B*59

Product number: 101.554-06u – without *Taq* polymerase

Lot number: 95K

Expiry date: 2013-August-01

Number of tests: 6 Number of wells per test: 8

Storage - pre-aliquoted primers: dark at -20°C

- PCR Master Mix: -20°C

This Product Description is only valid for Lot No. 95K.

CHANGES COMPARED TO THE PREVIOUS OLERUP SSP® HLA-B*59 Lot.

The HLA-B*59 specificity and interpretation tables have been updated for the HLA-B alleles described since the previous *Olerup* SSP® HLA-B*59 lot **(Lot No. 37G)**.

The HLA-B*59 primer set is unchanged compared to the previous lot.

101.554-06u – without *Taq* polymerase

General "Instructions for Use" IFU-02 Rev. No. 02 can be downloaded from

Lot No.: 95K Lot-specific information www.olerup-ssp.com

PRODUCT DESCRIPTION

HLA-B*59 SSP typing

CONTENT

The primer set contains 5'- and 3'-primers for identifying the B*59:01 to B*59:05 alleles.

PLATE LAYOUT

Each HLA-B*59 test consists of 8 PCR reactions in an 8 well cut PCR plate.

ı			•	4	_	•		•
ı	1	7	1 ~2	1	5	I 6	7	
ı			J	-	J	U	- 1	

The 8 well PCR plate is marked with 'B59' in silver/gray ink.

Well No. 1 is marked with the Lot No. '95K'.

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded.

The PCR plates are heat-sealed with a PCR-compatible foil.

Please note: When removing each 8 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

INTERPRETATION

The interpretation of HLA-B*59 SSP subtypings will be influenced by three B*07, B*08:09, several B*13, four B*15, the B*27:14, two B*35, seven B*39, several B*40, eight B*41, the B*42:04, seven B*44, most B*45, two B*46, most B*49, the B*50, most B*51, the B*52, the B*54, the B*55, the B*56, the B*58:08, the B*73, the B*78, three B*81, the B*82 and the B*83:01 alleles when present on the other haplotype.

UNIQUELY IDENTIFIED ALLELES

All the HLA-B*59, i.e. B*59:01 to B*59:05, recognized by the HLA Nomenclature Committee in October 2010¹ will be amplified by the primers in the HLA-B*59 SSP kit.

RESOLUTION IN HOMO- AND HETEROZYGOTES

A total of 5 alleles generate 5 amplification patterns that can be combined in 15 homozygous and heterozygous combinations. 4 of these genotypes do not give rise to unique amplification patterns.

```
++---+-
            *59:01, *59:04 = *59:04, *59:04
++----+ *59:01, *59:05 = *59:05, *59:05
```

¹HLA-B alleles listed on the IMGT/HLA web page 2010-Octoboer-15, release 3.2.0, www.ebi.ac.uk/imgt/hla.

General "Instructions for Use" IFU-02 Rev. No. 02 can be downloaded from

Lot No.: 95K Lot-specific information www.olerup-ssp.com

SPECIFICITY TABLE

HLA-B*59 SSP subtyping

Specificities and sizes of the PCR products of the 8 primer mixes used for HLA-B*59 SSP subtyping

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	Amplified HLA-B*59 alleles	Other amplified HLA-B alleles ³
1	430 bp	800 bp	*59:01-59:05	*54:12, 56:21
2 ⁴	105 bp	1070 bp	*59:01, 59:04-59:05	*07:78, 13:02:01-13:03, 13:08Q-13:09, 13:14-13:16, 13:18-13:19, 13:27, 13:30-13:34, 13:37-13:38, 13:40, 15:42, 35:60, 44:15, 44:18, 45:01, 45:03-45:08, 45:10-45:13, 46:11, 46:18, 49:01:01-49:03, 49:06-49:15, 50:01:01-50:02, 50:04-50:08, 50:10-50:11, 51:15, 54:01-54:03, 54:05N, 54:07-54:08N, 54:10, 54:12-54:13, 54:16-54:23, 55:01:01-55:01:03, 55:01:05-55:03, 55:05, 55:07, 55:09-55:12, 55:15-55:16, 55:18-55:19, 55:21-55:22, 55:24-55:26, 55:29-55:31, 55:33-55:38, 55:40-55:41, 55:43, 55:45-55:48, 56:01:01-56:01:04, 56:07-56:08, 56:13-56:14, 56:16-56:17, 56:19N-56:20, 56:23-56:30
3 ⁴	105 bp	1070 bp	*59:02	*07:84, 08:09, 13:35, 15:83, 27:14, 40:06:01:01-40:06:03, 40:44, 40:53, 40:70, 40:75, 40:83, 40:93, 40:95-40:96, 40:103, 40:109-40:110, 40:127, 40:131, 40:148, 41:01, 41:05-41:07, 41:09, 41:12, 41:14, 41:16, 42:04, 44:20, 44:47, 44:100, 51:01-51:03, 51:05, 51:07:01-51:12, 51:14, 51:16-51:24:04, 51:26-51:34, 51:36, 51:38-51:41N, 51:43-51:44N, 51:48-51:55, 51:57-51:58, 51:60-51:61, 51:65-51:80, 51:82-51:91, 51:93-51:96, 51:98N, 51:100-51:105, 52:01:01-52:13, 52:15-52:22, 54:04, 54:11,

IFU-02 Rev. No. 02 can be downloaded from

Lot No.: 95K **Lot-specific information** www.olerup-ssp.com

				54:15, 55:17, 55:20, 55:27-55:28, 56:05:01-56:06, 56:15, 56:21, 58:08, 78:01-78:07
4	150 bp	1070 bp		*54:12
5	400 bp	1070 bp		*07:65, 35:76, 44:90, 54:01- 54:06, 54:08N-54:23, 55:01:01- 55:05, 55:07-55:17, 55:19-55:33, 55:35-55:46, 55:48, 56:01:01- 56:13, 56:15-56:16, 56:18-56:22, 56:24-56:30, 81:01, 81:03?- 81:04N?, 82:01-82:03, 83:01
64	105 bp	1070 bp	*59:03	*15:137, 39:06:01-39:06:02, 39:33-39:34, 39:50, 39:57, 39:62, 40:86, 45:02, 50:09, 51:13:01-51:13:02, 51:92, 52:14, 55:13, 56:22, 73:01-73:02
7	180 bp	1070 bp	*59:04	*13:03, 15:73, 40:71, 44:10, 46:11, 51:15, 51:62, 51:106, 54:03, 56:01:01-56:02, 56:04, 56:07-56:08, 56:13-56:14, 56:16-56:17, 56:20, 56:24-56:30, 82:01-82:03
8	235 bp	1070 bp	*59:05	

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-B*59 SSP typings.

When the primers in a primer mix can give rise to specific PCR products of more than one length this is indicated if the size difference is 20 base pairs or more. Size differences shorter than 20 base pairs are not given. For high resolution SSP kits the respective lengths of the specific PCR product(s) of the alleles amplified by these primer mixes are given.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherit feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp internal positive control band in order to help in the correct orientation.

In the presence of a specific amplification the intensity of the control band often decreases.

³Due to the sharing of sequence motifs between HLA-B alleles non-HLA-B*59 alleles will be amplified by primer mixes 1 to 7.

⁴Short specific PCR fragments are less intense and not as sharp as longer specific bands.

^{&#}x27;?', nucleotide sequence information for the primer matching region not known.

General "Instructions for Use" IFU-02 Rev. No. 02 can be downloaded from

Lot No.: 95K Lot-specific information www.olerup-ssp.com

	-					-	•	
INTERPRETATION TABLE								
HLA-B*59 SSP subtyping								
Amplification pa	tterns	of the	B*59:0	1-59:0	5 allele	es		
	Well							
	1	2	3	4	5	6	7	8
Length of spec.	430	105	105	150	400	105	180	235
PCR product								
Length of int.	800	1070	1070	1070	1070	1070	1070	1070
pos. control ¹								
5'-primer ²	48	357	357	206	41	357	420	357
•	^{5'} -gCC ^{3'}	^{5'} -Tgg ^{3'}	^{5'} -Tgg ^{3'}	^{5'} -Agg ^{3'}	^{5'} -CTg ^{3'}	^{5'} -Tgg ^{3'}	^{5'} -TTA ^{3'}	^{5'} -Tgg ^{3'}
3'-primer ³	309	420	419	317	272	419	559	553
	^{5'} -ATC ^{3'}	^{5'} -gCT ^{3'}	^{5'} -CgT ^{3'}	^{5'} -ggA ^{3'}	^{5'} -TgT ^{3'}	^{5'} -CgA ^{3'}	^{5'} -CAg ^{3'}	^{5'} -CTg ^{3'}
Well No.	1	2	3	4	5	6	7	8
HLA-B allele								
*59:01	1	2						
*59:02	1		3					
*59:03	1					6		
*59:04	1	2					7	
*59:05	1	2						8
*07:65, 35:76, 44:90, 54:06,								
54:09, 54:14, 55:01:04, 55:04,					_			
55:08, 55:14, 55:23, 55:32,					5			
55:39, 55:42, 55:44, 56:03, 56:09-								
56:12, 56:18, 81:01, 83:01								
*07:78, 13:02:01-13:02:09,								
13:08Q-13:09, 13:14-13:16,								
13:18-13:19, 13:27, 13:30-13:34,								
13:37-13:38, 13:40, 15:42, 35:60,								
44:15, 44:18, 45:01, 45:03-45:08,		2						
45:10-45:13, 46:18, 49:01:01-								
49:03, 49:06-49:15, 50:01:01-								
50:02, 50:04-50:08, 50:10-50:11,								
54:07, 55:18, 55:34, 55:47, 56:23								
Well No.	1	2	3	4	5	6	7	8

IFU-02 Rev. No. 02 can be downloaded from

Lot No.: 95K Lot-specific information www.olerup-ssp.com

Length of spec.	430	105	105	150	400	105	180	235
PCR product								
Well No.	1	2	3	4	5	6	7	8
*07:84, 08:09, 13:35, 15:83,								
27:14, 40:06:01:01-40:06:03,								
40:44, 40:53, 40:70, 40:75,								
40:83, 40:93, 40:95-40:96,								
40:103, 40:109-40:110, 40:127,								
40:131, 40:148, 41:01, 41:05-								
41:07, 41:09, 41:12, 41:14,								
41:16, 42:04, 44:20, 44:47,								
44:100, 51:01:01-51:03, 51:05,			3					
51:07:01-51:12, 51:14, 51:16-								
51:24:04, 51:26-51:34, 51:36,								
51:38-51:41N, 51:43-51:44N,								
51:48-51:55, 51:57-51:58, 51:60-								
51:61, 51:65-51:80, 51:82-51:91,								
51:93-51:96, 51:98N, 51:100-								
51:105, 52:01:01-52:13, 52:15-								
52:22, 58:08, 78:01-78:07								
*13:03, 46:11, 51:15, 56:14,		2					7	
56:17							<i>'</i>	
*15:73, 40:71, 44:10, 51:62,							7	
51:106							'	
*15:137, 39:06:01-39:06:02,								
39:33-39:34, 39:50, 39:57, 39:62,								
40:86, 45:02, 50:09, 51:13:01-						6		
51:13:02, 51:92, 52:14, 73:01-								
73:02								
*54:01-54:02, 54:05N, 54:08N,								
54:10, 54:13, 54:16-54:23,								
55:01:01-55:01:03, 55:01:05-								
55:03, 55:05, 55:07, 55:09-55:12,		2			5			
55:15-55:16, 55:19, 55:21-55:22,		_						
55:24-55:26, 55:29-55:31, 55:33,								
55:35-55:38, 55:40-55:41, 55:43,								
55:45-55:46, 55:48, 56:19N								
*54:03, 56:01:01-56:01:04, 56:07-								
56:08, 56:13, 56:16, 56:20, 56:24-		2			5		7	
56:30								
Well No.	1	2	3	4	5	6	7	8

HLA-B*59 Product Insert

101.554-06u – without *Taq* polymerase General "Instruct

General "Instructions for Use" IFU-02 Rev. No. 02 can be downloaded from

Page 7 of 12

Lot No.: 95K Lot-specific information www.olerup-ssp.com

Length of spec.	430	105	105	150	400	105	180	235
PCR product								
Well No.	1	2	3	4	5	6	7	8
*54:04, 54:11, 54:15, 55:17,								
55:20, 55:27-55:28, 56:05:01-			3		5			
56:06, 56:15								
*54:12	1	2		4	5			
*55:13, 56:22					5	6		
*56:02, 56:04, 82:01-82:03					5		7	
*56:21	1		3		5			
*81:03-81:04N					?			
HLA-B allele								
Well No.	1	2	3	4	5	6	7	8

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control band.

²The nucleotide position, in the 1st or 3rd exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

³The nucleotide position, in the 2nd or 3rd exon, matching the specificity-determining 3'-end of the

³The nucleotide position, in the 2nd or 3rd exon, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

^{&#}x27;?', nucleotide sequence information for the primer matching region not known.

February 2011 Rev. No.: 00u information www.olerup-ssp.com

Lot No.: 95K Lot-specific information

	CELL LINE VALIDATION SHEET											
		HLA-B	*59 SS	P prim	er	se	t					
								W	ell			
					1	2	3	4	5	6	7	8
					_	2	3	4	2	9	7	8
				Prod. No.:	20062480	200624802	200624803	201081404	200964405	200850506	200964407	200964408
				7	624	624	624	081	796	850	796	796
) io	l Ö	Ö	Ö	20	Ö	Õ	Ö	Ö
	ILIV	VC cell line		<u></u> В*	(4	(4	(4	(4	(4	(1	(4	(1
1	9001		*07:02		-	-	_	-	-	-	-	-
2		LK707	*52:01	*73:01	-	-	+	-	-	+	-	-
3		E4181324	*52:01	70.01	-	-	+	-	-	Ė	-	-
4		GU373	*15:10	*53:01	-	-	÷	-	-	-	-	-
5		KAS011	*37:01	00.01	-	-	-	-	-	-	-	-
6	9353		*39:01	*51:01	-	-	+	-	-	-	-	-
7	9020	QBL	*18:01		-	-	-	-	-	-	-	-
8	9025		*35:01		-	-	-	-	-	-	-	-
9	9026		*38:01		-	-	-	-	-	-	-	-
10	9107	LKT3	*54:01		-	+	-	-	+	-	-	-
11	9051	PITOUT	*44:03		-	-	-	-	-	-	-	-
12	9052	DBB	*57:01		-	-	-	-	-	-	-	-
13	9004	JESTHOM	*27:05		-	-	-	-	-	-	-	-
14	9071	OLGA	*15:01	*15:20	-	-	-	-	-	-	-	-
15	9075	DKB	*40:01		-	-	-	-	-	-	-	-
16	9037	SWEIG007	*40:02		-	-	-	-	-	-	-	-
17	9282	CTM3953540	*08:01	*55:01	-	+	-	-	+	-	-	-
18		32367	*14:01	*56:01	-	+	-	-	+	-	+	-
19		BM16	*18:01		-	-	-	-	-	-	-	-
20		SLE005	*40:01		-	-	-	-	-	-	-	-
21		AMALA	*15:01		-	-	-	-	-	-	-	-
22		KOSE	*35:03		-	-	-	-	-	-	-	-
23	9124		*40:02	*56:02	-	-	-	-	+	-	+	-
24		JBUSH	*38:01		-	-	-	-	-	-	-	-
25		IBW9	*14:02		-	-	-	-	-	-	-	-
26		WT49 CH1007	*58:01	*F4.04	-	-	-	-	-	-	-	-
27			*07:05	*51:01 *44:03	-	-	+	-	-	-	-	-
28 29	9320	BEL5GB	*44:02 *44:03	44:03	-	-	-	-	-	-	-	-
30	9050		*42:01		-				-			-
31		DUCAF	*18:01		H			-	÷	-	H	÷
32	9297		*41:02			-	-	-	-	-	÷	-
33		MT14B	*40:01		-	-	-	-	-	-	-	-
34	9104		*38:01		_	-	-	-	-	-	-	-
35		SSTO	*44:02		-	-	-	-	-	-	-	-
36		KT17	*15:01	*35:01	-	-	-	-	-	-	-	-
37		HHKB	*07:02	00.01	-	-	-	-	-	-	-	-
38	9099		*15:01		-	-	-	-	-	-	-	-
39	9315		*08:01	*27:05	-	-	-	-	-	-	-	-
40		WHONP199	*13:02	*46:01	-	+	-	-	-	-	-	-
41		H0301	*14:02		-	-	-	-	-	-	-	-
42	9066	TAB089	*46:01		-	-	-	-	-	-	-	-
43	9076	T7526	*46:01		-	-	-	-	-	-	-	-
44	9057	TEM	*38:01		-	-	-	-	-	-	-	-
45	9239	SHJO	*42:01	*50:01	-	+	-	-	-	-	-	-
46	9013	SCHU	*07:02		-	-	-	-	-	-	-	-
47	9045	TUBO	*51:01		-	-	+	-	-	-	-	-
48	9303	TER-ND	*35:01	*44:03	-	-	-	-	-	-	-	-

HLA-B*59 Product Insert Page 9 of 12

101.554-06u - without *Taq* polymerase

General "Instructions for Use" IFU-02 Rev. No. 02 can be downloaded from

Lot No.: 95K Lot-specific information www.olerup-ssp.com

CERTIFICATE OF ANALYSIS

Olerup SSP® HLA-B*59 SSP

Product number: 101.554-06u – without *Taq* polymerase

Lot number: 95K

Expiry date: 2013-August-01

Number of tests: 6 Number of wells per test: 8

Well specifications:

Well No.	Production No.
1	2006-248-01
2	2006-248-02
3	2006-248-03
4	2010-814-04
5	2009-644-06
6	2008-505-06
7	2009-644-07
8	2009-644-08

The specificity of each primer solution of the HLA-B*59 primer set has been tested against 48 well characterized IHWC cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solution 4 and 8 were available. The specificities of the primers in primer solution 4 were tested by separately adding one additional 5'-primer, respectively one additional 3'-primer. In primer solution 8 it was only possible to test the 5'-primer, the 3'-primer was not possible to test.

Results: No false positive or false negative amplifications were obtained.

Date of approval: 2011-February-04

Approved by:

Quality Control, Supervisor



HLA-B*59 Product Insert Page 10 of 12

101.554-06u – without *Taq* polymerase

General "Instructions for Use" IFU-02 Rev. No. 02 can be downloaded from

Lot No.: 95K Lot-specific information www.olerup-ssp.com

Declaration of Conformity

Product name: Olerup SSP® HLA-B*59

Product number: 101.554-06u

Lot number: 95K

Intended use: HLA-B*59 high resolution histocompatibility testing

Manufacturer: Olerup SSP AB

Hasselstigen 1

SE-133 33 Saltsjöbaden, Sweden

Phone: +46-8-717 88 27 **Fax:** +46-8-717 88 18

We, *Olerup* SSP AB, hereby declare that this product, to which this Declaration of Conformity relates is in conformity with the following Standard(s) and other normative document(s) ISO 9001:2008 and ISO 13485:2003, following the provisions of the 98/79/EC Directive on *in vitro* diagnostic medical devices, Annex II List B, conformity assessed using Annex IV, as transposed into the national laws of the Member States of the European Union.

The Technical Documentation File is maintained at *Olerup* SSP AB, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden.

The Authorized Representative located within the Community is: Olerup SSP AB.

Notified Body: Lloyd's Register Quality Assurance Limited, Hiramford, Middlemarch Office Village, Siskin Drive, Coventry CV3 4FJ, United Kingdom. (Notified Body number: 0088.)

Saltsjöbaden, Sweden 2011-February-04

Olle Olerup Managing Director HLA-B*59 Product Insert Page 11 of 12 101.554-06u – without *Taq* polymerase General "Instructions for Use"

IFU-02 Rev. No. 02 can be downloaded from

Lot No.: 95K Lot-specific information www.olerup-ssp.com

HLA-B*59 Product Insert Page 12 of 12 General "Instructions for Use"

101.554-06u – without *Taq* polymerase

IFU-02 Rev. No. 02 can be downloaded from

Lot No.: 95K Lot-specific information www.olerup-ssp.com

Addresses:

Manufacturer:

Olerup SSP AB, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden.

Tel: +46-8-717 88 27 Fax: +46-8-717 88 18

E-mail: info-ssp@olerup.com

Web page: http://www.olerup-ssp.com

Distributed by:

Olerup GmbH, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

Tel: +43-1-710 15 00 Fax: +43-1-710 15 00 10

E-mail: support-at@olerup.com Web page: http://www.olerup.com

Olerup Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-OLERUP1 *Fax:* 610-344-7989

E-mail: info.us@olerup.com

Web page: http://www.olerup.com

For information on *Olerup* SSP distributors worldwide, contact **Olerup GmbH**.